Richmond Pharmacology is excited to announce that Dr. Jörg Taubel, Dr.Ulrike Lorch, Nobuo Ittetsu, and Minoru Takada will be attending BioJapan 2024in Yokohama. As Asia’s premier partnering event for the global biotechnologyindustry, BioJapan offers an unparalleled opportunity to engage with leaders inlife sciences, explore new business opportunities, and discuss the latestinnovations in biotechnology. The event will feature networking sessions,exhibitions, and one-on-one partnering meetings, making it a crucial gatheringfor industry professionals.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
